

Claim 15. (Amended/Clean) The method as claimed in claim 11, wherein the upper respiratory disease includes sinusitis or high airway diseases. *orig cl 2*  
*not def in spec*

13.2  
Cont.  
Claim 16. (Amended/Clean) The method as claimed in claim 11, wherein the medicine is used for treating human and veterinarian high airway diseases.

*Sub Assumtee*  
Claim 17. (Amended/Clean) The method as claimed in claim 11, wherein the medicine is used as a nasal releaser. *? orig cl 4*

Claim 18. (Amended/Clean) The method as claimed in claim 11, wherein the medicine is used for treating rhinitis.

Claim 19. (Amended/Clean) The method as claimed in claim 11, wherein the medicine is used as a clearing agent of nasal cavities and cheekbones. *? orig cl 6*

Claim 20. (Amended/Clean) The method as claimed in claim 12, wherein the pharmaceutically acceptable vehicle is 1,2,3-propanetriol.

Claim 21. (Amended/Clean) The method as claimed in claim 12, wherein the pharmaceutically acceptable vehicle is serum.

Claim 22. (Amended/Clean) The method as claimed in claim 12, wherein the pharmaceutically acceptable vehicle is 1,2-propanediol.

*inherent in cl 1-1*  
*duplication*  
Claim 23. (Amended/Clean) The method as claimed in claim 11, further comprising formulating a mixture of the alpha-hydroxypropionic acid and the pharmaceutically acceptable vehicle into a pharmaceutically acceptable form which is adapted to be administered to human and animal.

Salv  
C4  
B1  
cont.

Claim 24. (Amended/Clean) The method as claimed in claim 23, wherein the pharmaceutically acceptable form includes a solution for intake in drops, spray, and a fine powder.

Please add Claims 25 and 26:

B2

Claim 25. (New) A method of treating sinusitis and rhinitis in a human or animal in need thereof comprising administering through a nasal passageway of the human or animal a composition comprising:

an alpha-hydroxypropionic acid; and

a pharmaceutically acceptable vehicle;

wherein the alpha-hydroxypropionic acid is in a concentration of 0.2-10 vol.% based on the volume of the acceptable pharmaceutical vehicle.

wat org present

Claim 26. (New) A composition comprising an active component consisting of an alpha-hydroxypropionic acid or a pharmaceutical dilution thereof, wherein the active compound is linked to a vehicle, wherein the vehicle is a 1,2,3-propanetriol, a 1,2-propanediol, a serum, or any other acceptable pharmaceutic vehicle, and wherein the composition further comprises 0.2 – 10 volume percent of the active compound based on the volume of the vehicle.